… The phase III NCIC CTG PA.3 trial comparing gemcitabine plus erlotinib and gemcitabine
alone in advanced pancreatic cancer is the only trial of a targeted agent in pancreatic cancer …

… , two phase III studies of … studies cannot be extrapolated directly into erlotinib therapy,
considering the different results of two studies, the BR21 study of erlotinib (1) and the ISEL study of …

… EGFR-TKI (erlotinib) as a radiosensitizer for inoperable stage III NSCLC patients (pts) who
also received standard chemoradiotherapy (ChT/RT). Methods: 48 stage III NSCLC pts were …

… Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell
lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007; 25: …

… Some limitations to the study, however, must be taken into … launching this study, it failed to
show a benefit of erlotinib over … In addition, 26 % of the patients stopped erlotinib due to side …

… The 1-year survival rate of 39.4% achieved in the TRUST population is comparable with 1-year
survival rates observed in phase III studies with docetaxel (30 − 37%) [7], [8], [9] or …

… of PA.3 study, two large phase III studies provided alternative first-line approaches for the
treatment of APC in patients with good performance status (PS) [7, 8]. In the MPACT study, the …

… in patients with non-small cell lung cancer. The aim of this study was to evaluate the efficacy
of erlotinib … -controlled phase III trial in previously treated patients with an advanced NSCLC, …

… Furthermore, most NSCLC patients are diagnosed with stage III or IV disease. Stage IIIA …
Surgery, radiotherapy, and chemotherapy are the primary modalities of stage III NSCLC …

… We believe that EGFR-TKI are active in EGFR wild-type tumors, but they are inferior to
standard CT, as shown in the phase III TORCH trial, where in an unselected population erlotinib …